Lipoprotein particle concentrations may explain the absence of coronary protection in the women's health initiative hormone trials

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 9, 2008, Pages 1666-1671

  Hsia, Judith ^a,i   Otvos, James D ^b   Rossouw, Jacques E ^c   Wu, Lieling ^d   Wassertheil Smoller, Sylvia ^e   Hendrix, Susan L ^f   Robinson, Jennifer G ^g   Lund, Bernedine ^d   Kuller, Lewis H ^h  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b LIPOSCIENCE INC   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f DETROIT MEDICAL CENTER   (United States)

^g UNIVERSITY OF IOWA   (United States)

^h UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ ASTRAZENECA   (United Kingdom)

Author keywords

Coronary heart disease; Estrogen; Lipoproteins; Women

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN PARTICLE; PLACEBO; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; LIPOPROTEIN; MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART PROTECTION; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UTERUS; BLOOD; CHEMICALLY INDUCED DISORDER; CORONARY ARTERY DISEASE; DOWN REGULATION; ESTROGEN THERAPY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RISK; RISK ASSESSMENT; TREATMENT OUTCOME; UPREGULATION; WOMEN'S HEALTH;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DOWN-REGULATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; HYSTERECTOMY; LIPOPROTEINS; MAGNETIC RESONANCE SPECTROSCOPY; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; RISK ASSESSMENT; TREATMENT OUTCOME; UP-REGULATION; WOMEN'S HEALTH;

EID: 51649083308     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.170431     Document Type: Article

References (21)

1. Writing Group for the Women's Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women. Principal Results From, the Women's Health Initiative Randomized Controlled Trial. JAMA. 2002;288:321-333.
2. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen on postmenopausal women with hysterectomy: The Women's Health. Initiative Randomized Controlled Trial. JAMA. 2004;291:1701-1712.
3. Manson. JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black. HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M. Estrogen plus progestin and risk of coronary heart disease. N Engl J Med. 2003;349:523-534.
4. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix S, Pettinger M, Caralis P, Crawford S, Eaton CB, Greep N, Heckbert SR, Kostis JB. Conjugated equine estrogens and the risk of coronary heart disease. Arch Intern Med. 2006;166:357-365.
5. Kuller L, Arnold A, Tracy R, Otvos J, Burke O, Psaty B, Siscovick D, Freedman DS, Kronmal R. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vase. Biol, 2002;22:1175-1180.
6. Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein, particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in. women. Circulation. 2002; 106:1930-1937.
7. Mackey RH, Kuller LH, Sutton-Tyrrell K, Evans RW, Holubkov R, Matthews KA. Hormone therapy, lipoprotein subclasses, and coronary calcification. The Healthy Women Study. Arch Intern. Med. 2005; 165: 510-515.
8. The Women's Health Initiative Study Group. Design of the Women's Health Initiative Clinical Trial and Observational Study. Control Clin Trials. 1998;19:61-109.
9. Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol. 2003;13: S78-S86.
10. Curb JD, McTieman A, Heckbert SR, et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol, 2003;13:S122-S128.
11. Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem, 1992;38:1632-1638.
12. Hastie TJ, Tibshirani RJ. Generalized Additive Models. New York: Chapman and Hall, 1990.
13. Vickers MR, MacLennan AH, Lawton B, Ford D, Martin. J, Meredith SK, DeStavola BL, Rose S, Dowell A, Wilkes HC, Darbyshire JH, Meade TW, for the WISDOM team. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomized controlled trial of hormone replacement therapy in postmenopausal women. BMJ. 2007;335:239.
14. Hsia J, Heiss G, Ren H, Allison M, Dolan NC, Greenland P, Heckbert SR, Johnson KC, Manson JE, Sidney S, Trevisan M, for the WHI Investigators. Calcium/vitamin D supplementation and cardiovascular events. Circulation. 2007;115:846-854.
15. Robins SJ, Collins D, Wittes JT, Papdemetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB. Relation of gemfibrozil treatment and lipid levels with, major coronary events: VA-HIT: a randomized controlled, trial. JAMA. 2001; 285:1585-1591.
16. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. Primary prevention, of cardiovascular disease with atorvastatin in. type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized, placebo-controlled trial. Lancet. 2004;364: 685-696.
17. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, Bloomsfield HE, Robins SJ. Low-density lipoprotein and high-density lipoprotein, particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in. the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation, 2006; 113: 1556-1563.
18. Soedamah-Muthu SS, Colhoun HM, Thomason MJ, Betteridge DJ, Durrington. PN, Hitman GA, Fuller JH, Julier K, Mackness MI, Neil HAW. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein, subclasses in type 2 diabetic pateints with ischaemic heart disease. Atherosclerosis. 2003;167:243-255.
19. Kooperberg C, Cushman M, Hsia J, Robinson JG, Aragaki AK, Lynch JK, Baird AE, Johnson KC, Kuller IH, Beresford SAA, Rodriguez B. Can biomarkers identify women, at increased stroke risk? The Women's Health Initiative Hormone Trials. PIoS Clinical Trials. 2007;2:e28.
20. Reuben DB, Palla SL, Hu P, Reboussin BA, Crandall C, Herrington DM, Barrett-Connor E, Greendale GA. Progestins affect mechanism of estrogen-induced C-reactive protein, stimulation. Am. J Med. 2006;119: 167.el-e8.
21. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E; Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. JAMA. 1998;280:605-613.